MedTrace Logo

Investigating Myosteatosis in Steatotic Liver Diseases

NCT06514300 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-07-23

No results posted yet for this study

Summary

Steatotic liver diseases (SLD) are the most common chronic liver diseases worldwide. SLD are defined by an excessive liver lipid content (steatosis) of more than 5% of the total liver weight and includes 3 clinical entities : metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD) and a mixed entity combining the two settings referred as MetALD. SLD are associated to extra-hepatic complications such as cardiovascular diseases, insulin resistance or muscle changes. Among the latter, myosteatosis, defined by an excessive muscle fat content, has been reported as a muscle change in MASLD occuring even in non-cirrhotic stages. Investigators will explore these muscle changes in SLD patients according to the severity of the underneath liver disease.

Conditions

  • Alcohol-related Liver Disease
  • Metabolic Dysfunction Associated Steatotic Liver Disease
  • Steatotic Liver Disease of Mixed Origin (MetALD)
  • Steatotic Liver Diseases
  • Myosteatosis
  • Magnetic Resonance Imaging
  • Magnetic Resonance Spectroscopy
  • Liver Histology

Sponsors & Collaborators

  • Fonds National de la Recherche Scientifique

    collaborator OTHER

  • Concerted Research Action

    collaborator UNKNOWN

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Nicolas Lanthier, MD, PhD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-22
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06514300 on ClinicalTrials.gov